PS Fertility Announces Successful Completion of Series A Funding

Charlottesville, VA (June 3, 2025) — PS Fertility, the leading pioneer in the field of male fertility diagnostic testing, announced the successful completion of its $3.5 million Series A Preferred funding round. 

The round was led by existing investors Flourish Investments LLC and the Cassiopeia Foundation, Inc, along with continued support from the Virginia Innovation Partnership Corporation as well as new key investors, Moses Gate Holdings LLC and CAV Angels. This new capital positions the company on solid financial footing and provides the momentum needed to scale PS Detect and accelerate further innovation in male fertility diagnostics.

PS Detect is a first-generation mail-order diagnostic test that assesses the percentage of sperm cells with phosphatidylserine (PS), a critical biomarker required to achieve fertilization. Studies performed by PS Fertility, including a November 2024 article published in JU Open Plus, provide clear evidence of the correlation between this biomarker and fertilization.  

PS Detect complements the standard semen analysis by providing a more complete picture of male fertility, as studies show that 20%-30% of men with a normal standard semen analysis are, in fact, infertile. PS has been proven to be correlated with fertility and to provide a more accurate assessment of male fertility.  

Low PS levels are especially prevalent in men with a varicocele, as it was found in one study that 44% of men with a varicocele had a PS Score below normal.  A varicocele is an enlargement of veins in the scrotum and a common cause of infertility in men.   

“PS Fertility is excited to bring meaningful new science, diagnostics and treatments to the male population experiencing fertility challenges,” shares co-founder and CEO Kevin Combs.   

PS Fertility was also co-founded by Kodi Ravichandran, PhD and Jeff Lysiak, PhD. It leverages their patent pending research work on male fertility and cellular biology done at the University of Virginia Medical School. 

“With infertility impacting 1 in 6 couples, the need for improved fertility diagnostics has never been greater,” says Lysiak, co-founder and Chief Scientific Officer of PS Fertility. “PS Fertility is proud to lead the way with tests that go beyond traditional semen analysis.”     

PS Detect is the first in what is expected to be a series of commercially marketed diagnostics and products. PS Fertility will continue to use these important discoveries in the fertilization process to drive innovation and develop accessible fertility solutions. 

Ask your doctor or email us at info@psfertility.com to take your next step.

PS Fertility is committed to revolutionizing male fertility diagnostics by equipping physicians and patients with advanced tools to uncover the root causes of infertility. By offering innovative solutions like PS Detect, PS Fertility is empowering more couples to get fertility answers. For more information, visit www.psfertility.com.